latest
Uncategorised Articles

November 2nd, 2017: “EURETINA-Brief”© Issue No. 164

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the November 2nd, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story

Established rheumatoid arthritis (RA) drug from AbbVie (adalimumab) shows promise in the treatment of uveitis

An international research collaboration between US and EU clinical investigators, led by Duke University, Durham, North Carolina, has shown that adalimumab, an anti-TNF-α antagonist, marketed by AbbVie Inc. (NYSE: ABBV), may have application in the treatment of active noninfectious intermediate uveitis, posterior uveitis, or panuveitis. The drug, a recombinant DNA-derived human immunoglobulin G1 (IgG1) monoclonal […]

Read full story

January 18th, 2016: “EURETINA-Brief”© Issue No. 125

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the January 18th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story

Related Uncategorised News